ADULT AMBULATORY INFUSION ORDER

Epoetin Alfa-epbx (RETA CRIT)
Maintenance Injection for Non-Oncology

Weight: ___________kg    Height: ___________cm

Allergies: ________________________________________________

Diagnosis Code: __________________________________________

Treatment Start Date: ___________ Patient to follow up with provider on date: ___________

**This plan will expire after 365 days at which time a new order will need to be placed**

**This order set is for MAINTENANCE DOSING ONLY. Patients should have received first dose via the INITIATION order set with a non-oncology indication checked**

**If your patient has an ONCOLOGY INDICATION, DO NOT use this form. Please use the form for maintenance in oncology patients**

Indication: ______________________________________________

GUIDELINES FOR ORDERING
1. Send FACE SHEET and H&P or most recent chart note.
2. OHSU’s formulary erythropoiesis stimulating agent (ESA) is darbepoetin alfa (ARANESP). All orders for epoetin alfa-epbx (RETA CRIT) will be converted to darbepoetin alfa using equivalent therapeutic interchange dosing listed in the table below. Providers who prefer to use epoetin alfa-epbx must specify a reason for its use. REASON FOR EPOETIN USE: _____________________________________________

3. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day. Patients may be on prophylactic oral iron supplementation concurrent with ESA treatment as long as supplementation for the prevention of iron deficiency is necessary due to ESA therapy alone.

4. Serum ferritin and transferrin saturation (TSAT) must be performed every month during initial (ESA) treatment and at least every 3 months during stable ESA treatment (serum ferritin greater than 100 ng/mL, and TSAT greater than or equal to 20%). Therapy with epoetin alfa-epbx may continue only if hemoglobin DOES NOT equal or exceed 11 g/dL.

5. For patients with anemia of CKD: The medical record must display documentation that anemia is clearly attributed to a CKD diagnosis. The specific CKD stage must be moderate (stage III) to end stage

LABS:
☐ Hemoglobin & Hematocrit, Routine, ONCE, every ______ (visit)(days)(weeks)(months) – Circle One
☐ CMP, Routine, ONCE, (every 12 weeks) or every ______ (visit)(days)(weeks)(months) – Circle One
☐ Ferritin (serum), Routine, ONCE, (every 12 weeks) or every ______ (visit)(days)(weeks)(months) – Circle One
☐ Iron and TIBC (serum), Routine, ONCE, (every 12 weeks) or every ______ (visit)(days)(weeks)(months) – Circle One
☐ Labs already drawn. Date: ________ (Must have been drawn at least 14 days after the last dose)
NURSING ORDERS:
1. Patients receiving concurrent treatment with Iron Sucrose (VENOFER) and/or Vitamin B12 cannot receive ESA treatment on the same day.
2. TREATMENT PARAMETERS – Hold treatment and call provider if hemoglobin is greater than or equal to 11, most recent serum ferritin is less than or equal to 100 ng/mL, transferrin saturation is less than 20% or if blood pressure is greater than 180 systolic or 100 diastolic.
3. Follow facility policies and/or protocols for vascular access maintenance with appropriate flush solution, declotting (alteplase), and/or dressing changes.

MEDICATIONS:

- epoetin alfa-epbx (RETACRIT), subcutaneous, ONCE
  *Pharmacist will round dose to nearest vial size if within 10% of original dose during verification*

Weight based regimen:

- Dose
  - □ _________ units/kg = _________ units

- Interval:
  - □ Weekly x _________ weeks
  - □ _________ times per week x _________ weeks

Fixed dose regimens:

- Dose:
  - □ 2,000 units
  - □ 3,000 units
  - □ 4,000 units
  - □ 10,000 units
  - □ 20,000 units
  - □ 40,000 units

- Interval:
  - □ Weekly x _________ weeks
  - □ _________ times per week x _________ weeks
**ADULT AMBULATORY INFUSION ORDER**

**Epoetin alfa-epbx (RETCRIT)**

**Maintenance Injection for Non-Oncology**

---

**ACCOUNT NO.**

**MED. REC. NO.**

**NAME**

**BIRTHDATE**

---

**ALL ORDERS MUST BE MARKED IN INK WITH A CHECKMARK (✓) TO BE ACTIVE.**

---

**OTHER:**

**Conversion from epoetin alfa-epbx (RETCRIT) to darbepoetin alfa (ARANESP): Initial adult dosing**

<table>
<thead>
<tr>
<th>Epoetin alfa-epbx dose (units/week)</th>
<th>Darbepoetin alfa dose (mcg/week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;1500</td>
<td>6.25</td>
</tr>
<tr>
<td>1500-2499</td>
<td>6.25</td>
</tr>
<tr>
<td>2500-4999</td>
<td>12.5</td>
</tr>
<tr>
<td>5000-10,999</td>
<td>25</td>
</tr>
<tr>
<td>11,000-17,999</td>
<td>40</td>
</tr>
<tr>
<td>18,000-33,999</td>
<td>60</td>
</tr>
<tr>
<td>34,000-89,999</td>
<td>100</td>
</tr>
<tr>
<td>≥90,000</td>
<td>200</td>
</tr>
</tbody>
</table>

In patients receiving epoetin alfa-epbx 2-3 times weekly, darbepoetin should be given once weekly. If epoetin is administered once weekly, darbepoetin should be given once every 2 weeks. Darbepoetin dosing every 2 weeks should be determined by adding the 2 weekly epoetin alfa-epbx doses, then convert to appropriate corresponding darbepoetin dose. Doses should be titrated to hemoglobin response thereafter.

**By signing below, I represent the following:**

I am responsible for the care of the patient (who is identified at the top of this form);

I hold an active, unrestricted license to practice medicine in: □ Oregon □ __________________ (check box that corresponds with state where you provide care to patient and where you are currently licensed. Specify state if not Oregon);

My physician license Number is # __________________ (MUST BE COMPLETED TO BE A VALID PRESCRIPTION); and I am acting within my scope of practice and authorized by law to order Infusion of the medication described above for the patient identified on this form.

---

**Provider signature: ____________________________ Date/Time: ____________________________**

**Printed Name:__________________________ Phone: __________________ Fax:__________________________**
ADULT AMBULATORY INFUSION ORDER

**Epoetin alfa-epbx (RETA CRIT)**
Maintenance Injection for Non-Oncology

Olc Central Intake Nurse:
Phone: 971-262-9645 (providers only) Fax: 503-346-8058

**Please check the appropriate box for the patient’s preferred clinic location:**

- **Beaverton**
  OHSU Knight Cancer Institute
  15700 SW Greystone Court
  Beaverton, OR 97006
  Phone number: 971-262-9000
  Fax number: 503-346-8058

- **NW Portland**
  Legacy Good Samaritan campus
  Medical Office Building 3, Suite 150
  1130 NW 22nd Ave.
  Portland, OR 97210
  Phone number: 971-262-9600
  Fax number: 503-346-8058

- **Gresham**
  Legacy Mount Hood campus
  Medical Office Building 3, Suite 140
  24988 SE Stark
  Gresham, OR 97030
  Phone number: 971-262-9500
  Fax number: 503-346-8058

- **Tualatin**
  Legacy Meridian Park campus
  Medical Office Building 2, Suite 140
  19260 SW 65th Ave.
  Tualatin, OR 97062
  Phone number: 971-262-9700
  Fax number: 503-346-8058

Infusion orders located at: [www.ohsuknight.com/infusionorders](http://www.ohsuknight.com/infusionorders)